^
    Back
    Association details:
    Biomarker:FGFR2 N549K
    Cancer:Endometrial Cancer
    Drug:Lytgobi (futibatinib) (FGFR inhibitor) +
    MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors

    Published date:
    05/15/2020
    Excerpt:
    Human endometrial FGFR2-N549K-mutated AN3CA cancer cells were treated with futibatinib plus either everolimus or MK2206 or with each agent alone…In ANC3A cells, the combination of futibatinib with MK2206 inhibited AKT phosphorylation; futibatinib plus either MK2206 or everolimus inhibited mTOR phosphorylation to a greater degree than monotherapy...The combination of futibatinib plus a PI3K pathway inhibitor resulted in synergistic antitumor effects.
    DOI:
    10.1158/1538-7445.AM2020-659